LRSAM1 variants and founder effect in French families with ataxic form of Charcot-Marie-Tooth type 2.
Adaptor Proteins, Signal Transducing
/ genetics
Alleles
Amino Acid Sequence
Biopsy
Cell Cycle Proteins
/ genetics
Charcot-Marie-Tooth Disease
/ diagnosis
Family
Founder Effect
France
Genetic Testing
Genetic Variation
Humans
Nuclear Proteins
/ genetics
Pedigree
Phenotype
Ubiquitin-Protein Ligases
/ chemistry
Journal
European journal of human genetics : EJHG
ISSN: 1476-5438
Titre abrégé: Eur J Hum Genet
Pays: England
ID NLM: 9302235
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
06
09
2018
accepted:
26
03
2019
revised:
17
03
2019
pubmed:
19
4
2019
medline:
13
6
2020
entrez:
19
4
2019
Statut:
ppublish
Résumé
Currently only 25-30% of patients with axonal forms of Charcot-Marie-Tooth disease (CMT) receive a genetic diagnosis. We aimed to identify the causative gene of CMT type 2 in 8 non-related French families with a distinct clinical phenotype. We collected clinical, electrophysiological, and laboratory findings and performed genetic analyses in four different French laboratories. Seventy-two patients with autosomal dominant inheritance were identified. The disease usually started in the fourth decade and the clinical picture was dominated by sensory ataxia (80%), neuropathic pain (38%), and length-dependent sensory loss to all modalities. Electrophysiological studies showed a primarily axonal neuropathy, with possible isolated sensory involvement in milder phenotypes. Disease severity varied greatly but the clinical course was generally mild. We identified 2 novel variants in LRSAM1 gene: a deletion of 4 amino acids, p.(Gln698_Gln701del), was found in 7 families and a duplication of a neighboring region of 10 amino acids, p.(Pro702_Gln711dup), in the remaining family. A common haplotype of ~450 kb suggesting a founder effect was noted around LRSAM1 in 4 families carrying the first variant. LRSAM1 gene encodes for an E3 ubiquitin ligase important for neural functioning. Our results confirm the localization of variants in its catalytic C-terminal RING domain and broaden the phenotypic spectrum of LRSAM1-related neuropathies, including painful and predominantly sensory ataxic forms.
Identifiants
pubmed: 30996334
doi: 10.1038/s41431-019-0403-8
pii: 10.1038/s41431-019-0403-8
pmc: PMC6777460
doi:
Substances chimiques
Adaptor Proteins, Signal Transducing
0
Cell Cycle Proteins
0
MAD2L1BP protein, human
0
Nuclear Proteins
0
LRSAM1 protein, human
EC 2.3.2.27
Ubiquitin-Protein Ligases
EC 2.3.2.27
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1406-1418Références
Skre H. Genetic and clinical aspects of Charcot-Marie-Tooth's disease. Clin Genet. 1974;6:98–118.
doi: 10.1111/j.1399-0004.1974.tb00638.x
Pareyson D, Marchesi CDiagnosis. natural history, and management of Charcot-Marie-Tooth disease. Lancet Neurol. 2009;8:654–67.
doi: 10.1016/S1474-4422(09)70110-3
Harding AE, Thomas PK. The clinical features of hereditary motor and sensory neuropathy types I and II. Brain. 1980;103:259–80.
doi: 10.1093/brain/103.2.259
Berciano J, García A, Gallardo E, Peeters K, Pelayo-Negro AL, Álvarez-Paradelo S, et al. Intermediate Charcot-Marie-Tooth disease: an electrophysiological reappraisal and systematic review. J Neurol. 2017;264:1655–77.
doi: 10.1007/s00415-017-8474-3
Pisciotta C, Shy ME. Neuropathy. Neuromolecular Med. 2018;148:653–65.
Rossor AM, Polke JM, Houlden H, Reilly MM. Clinical implications of genetic advances in Charcot-Marie-Tooth disease. Nat Rev Neurol. 2013;9:562–71.
doi: 10.1038/nrneurol.2013.179
Hakonen JE, Sorrentino V, Avagliano Trezza R, de Wissel MB, van den Berg M, Bleijlevens B, et al. LRSAM1-mediated ubiquitylation is disrupted in axonal Charcot-Marie-Tooth disease 2P. Hum Mol Genet. 2017;26:2034–41.
doi: 10.1093/hmg/ddx089
Guernsey DL, Jiang H, Bedard K, Evans SC, Ferguson M, Matsuoka M, et al. Mutation in the gene encoding ubiquitin ligase LRSAM1 in patients with Charcot-Marie-Tooth disease. PLoS Genet. 2010;6:e1001081.
doi: 10.1371/journal.pgen.1001081
Weterman MA, Sorrentino V, Kasher PR, Jakobs ME, van Engelen BG, Fluiter K, et al. A frameshift mutation in LRSAM1 is responsible for a dominant hereditary polyneuropathy. Hum Mol Genet. 2012;21:358–70.
doi: 10.1093/hmg/ddr471
Nicolaou P, Cianchetti C, Minaidou A, Marrosu G, Zamba-Papanicolaou E, Middleton L, et al. A novel LRSAM1 mutation is associated with autosomal dominant axonal Charcot-Marie-Tooth disease. Eur J Hum Genet. 2013;21:190–4.
doi: 10.1038/ejhg.2012.146
Engeholm M, Sekler J, Schöndorf DC, Arora V, Schittenhelm J, Biskup S, et al. A novel mutation in LRSAM1 causes axonal Charcot-Marie-Tooth disease with dominant inheritance. BMC Neurol. 2014;14:118.
doi: 10.1186/1471-2377-14-118
Peeters K, Palaima P, Pelayo-Negro AL, García A, Gallardo E, García-Barredo R, et al. Charcot-Marie-Tooth disease type 2G redefined by a novel mutation in LRSAM1. Ann Neurol. 2016;80:823–33.
doi: 10.1002/ana.24775
Hu B, Arpag S, Zuchner S, Li J. A novel missense mutation of CMT2P alters transcription machinery. Ann Neurol. 2016;80:834–45.
doi: 10.1002/ana.24776
Zhao G, Song J, Yang M, Song X, Liu X. A novel mutation of LRSAM1 in a Chinese family with Charcot-Marie-Tooth disease. J Peripher Nerv Syst. 2018;23:55–9.
doi: 10.1111/jns.12247
Sommer CL, Brandner S, Dyck PJ, Harati Y, LaCroix C, Lammens M, et al. Peripheral Nerve Society Guideline on processing and evaluation of nerve biopsies. J Peripher Nerv Syst. 2010;15:164–75.
doi: 10.1111/j.1529-8027.2010.00276.x
Bacquet J, Stojkovic T, Boyer A, Martini N, Audic F, Chabrol B, et al. Molecular diagnosis of inherited peripheral neuropathies by targeted next-generation sequencing: molecular spectrum delineation. BMJ Open. 2018;8:e021632.
doi: 10.1136/bmjopen-2018-021632
Masingue M, Perrot J, Carlier RY, Piguet-Lacroix G, Latour P, Stojkovic T. WES homozygosity mapping in a recessive form of Charcot-Marie-Tooth neuropathy reveals intronic GDAP1 variant leading to a premature stop codon. Neurogenetics. 2018;19:67–76.
doi: 10.1007/s10048-018-0539-7
Chahin N, Sorenson EJ. Serum creatine kinase levels in spinobulbar muscular atrophy and amyotrophic lateral sclerosis. Muscle Nerve. 2009;40:126–9.
doi: 10.1002/mus.21310
Luigetti M, Modoni A, Renna R, Silvestri G, Ricci E, Montano N, et al. A case of CMT 1B due to Val 102/fs null mutation of the MPZ gene presenting as hyperCKemia. Clin Neurol Neurosurg. 2010;112:794–7.
doi: 10.1016/j.clineuro.2010.05.001
Berciano J, García A, Peeters K, Gallardo E, De Vriendt E, Pelayo-Negro AL, et al. NEFL E396K mutation is associated with a novel dominant intermediate Charcot-Marie-Tooth disease phenotype. J Neurol. 2015;262:1289–300.
doi: 10.1007/s00415-015-7709-4
Aerts MB, Weterman AJ, Quadri M, Schelhaas HJ, Bloem BR, Esselink RA, et al. A LRSAM1 mutation links Charcot-Marie-Tooth type 2 to Parkinson's disease. Ann Clin Transl Neurol. 2015;3:146–9.
doi: 10.1002/acn3.281
Tang B, Seredenina T, Coppola G, Kuhn A, Geschwind DH, Luthi-Carter R, et al. Gene expression profiling of R6/2 transgenic mice with different CAG repeat lengths reveals genes associated with disease onset and progression in Huntington's disease. Neurobiol Dis. 2011;42:459–67.
doi: 10.1016/j.nbd.2011.02.008
Trempe JF, Sauvé V, Grenier K, Seirafi M, Tang MY, Ménade M, et al. Structure of parkin reveals mechanisms for ubiquitin ligase activation. Science. 2013;340:1451–5.
doi: 10.1126/science.1237908
Bogdanik LP, Sleigh JN, Tian C, Samuels ME, Bedard K, Seburn KL, et al. Loss of the E3 ubiquitin ligase LRSAM1 sensitizes peripheral axons to degeneration in a mouse model of Charcot-Marie-Tooth disease. Dis Model Mech. 2013;6:780–92.
doi: 10.1242/dmm.010942
Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem. 1998;67:425–79.
doi: 10.1146/annurev.biochem.67.1.425
Amit I, Yakir L, Katz M, Zwang Y, Marmor MD, Citri A, et al. Tal, a Tsg101-specific E3 ubiquitin ligase, regulates receptor endocytosis and retrovirus budding. Genes Dev. 2004;18:1737–52.
doi: 10.1101/gad.294904